Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Skba Capital Management LLC

Skba Capital Management LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 24,160 shares of the medical research company’s stock after buying an additional 3,600 shares during the quarter. Skba Capital Management LLC’s holdings in Amgen were worth $6,297,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its holdings in Amgen by 3.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 328,563 shares of the medical research company’s stock worth $86,810,000 after buying an additional 10,946 shares during the last quarter. Joseph Group Capital Management raised its position in shares of Amgen by 15.1% during the 4th quarter. Joseph Group Capital Management now owns 9,934 shares of the medical research company’s stock valued at $2,589,000 after acquiring an additional 1,301 shares in the last quarter. Portland Global Advisors LLC raised its position in shares of Amgen by 0.9% during the 4th quarter. Portland Global Advisors LLC now owns 23,755 shares of the medical research company’s stock valued at $6,192,000 after acquiring an additional 205 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Amgen during the fourth quarter worth $8,798,000. Finally, Allianz SE acquired a new position in Amgen in the fourth quarter worth $9,933,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. UBS Group reissued a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Saturday. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Truist Financial reduced their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $314.04.

Insider Buying and Selling

In other Amgen news, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last three months. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Up 0.4 %

AMGN opened at $306.95 on Monday. The firm has a market cap of $164.90 billion, a P/E ratio of 40.66, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The business has a 50 day moving average price of $301.08 and a 200 day moving average price of $297.94. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.